melanotan II comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-06-17. Where a claim depends on a specific study, the study is described rather than over-claimed.
Lyophilized peptide powder is generally stored frozen, protected from light and moisture. Tryptophan residues are susceptible to oxidation, and the lactam bridge can hydrolyze under strongly acidic or basic conditions. Solutions prepared for laboratory work degrade faster than dry powder, and repeated freeze-thaw cycles accelerate loss. Common practice is to aliquot solutions before freezing and to avoid alkaline buffers. Reported stability windows vary with concentration, buffer, and temperature, so exact shelf lives are method-specific rather than universal.
Regulatory status differs by country, and in many places supplying the compound for human consumption is unlawful. Vendors frequently label material as intended for research use only, a designation that shifts stated purpose but does not create a legal pathway for personal use. Certificates of analysis accompanying such products vary widely in detail and provenance. Third-party testing exists but is voluntary, and results are rarely linked to a specific lot in a publicly verifiable way.
Identity testing for a synthetic peptide relies on several complementary methods. Reversed-phase high-performance liquid chromatography separates the target from related impurities and reports purity as a percentage of total peak area. Mass spectrometry confirms molecular mass and can reveal deletions or truncations. Amino acid analysis and peptide mapping provide sequence-level confirmation, while counter-ion content and residual solvents are measured separately. A purity figure alone does not establish identity, so a complete dataset combines chromatographic and spectrometric evidence.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Free base; salt forms differ |
| Molecular mass | About 1024.2 g/mol | Monoisotopic value for the free base |
| Appearance | White to off-white lyophilized powder | Visual inspection is not an identity test |
| Solubility | Soluble in water and polar organic solvents | Dissolution depends on salt form and pH |
| Typical storage | -20 °C, dry, protected from light | Powder is more stable than prepared solutions |
Solid peptide kept dry at minus twenty degrees Celsius, shielded from light and moisture, is generally considered stable for extended periods. Solutions are divided into single-use aliquots and held at minus twenty or minus eighty degrees Celsius, because repeated freeze-thaw cycles promote aggregation and loss of material to container surfaces. Hydrolysis of the backbone and oxidation of tryptophan are the principal degradation routes in aqueous solution, and both accelerate at ambient temperature. Hygroscopic uptake after a vial is opened can also shift the actual mass weighed, which affects any concentration calculated from it.
Routine characterisation relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres, using a C18 column and a water-acetonitrile gradient containing trifluoroacetic acid. Electrospray ionisation mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidised by-products that co-elute poorly. Sequence and stereochemistry require additional work, such as peptide mapping or amino acid analysis, because a chromatographic purity figure alone does not distinguish a diastereomer from the target peptide. Independent testing of research-grade material frequently shows measured content below the stated label, so a certificate of analysis is best read together with the method that produced it.
Melanotan-2 is handled in the laboratory as a lyophilised powder that dissolves readily in water, dimethyl sulfoxide and dimethylformamide, with limited solubility in ethanol. Stock solutions prepared in an organic solvent often precipitate when diluted into aqueous buffer, so gradual dilution with mixing is standard practice. The peptide carries a tryptophan residue and a histidine residue, both sensitive to oxidation and to alkaline conditions. Working solutions are therefore kept near neutral to slightly acidic pH, protected from light, and consumed within the same working session whenever that is practical.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Regulatory treatment of this peptide varies by country. It holds no marketing authorization as a medicine in the United States, the European Union, or most other jurisdictions. Some countries classify products containing it as prescription-only or unlicensed medicines, which restricts lawful supply. Authorities have issued public notices warning that unregulated products may contain undeclared or incorrect ingredients. The molecule also appears on prohibited lists for competitive sport. These measures address supply oversight rather than any approved therapeutic role.
Published research on the compound remains limited. Much of the human data comes from small, early-stage studies rather than large controlled trials, and several questions about effects and variability between individuals remain open. Investigators have examined receptor activity, pigment pathways, and related physiological responses in laboratory and animal models. Findings from those models do not automatically translate to human outcomes. Reviews frequently note the scarcity of rigorous clinical evidence and call for better-characterized study material.
Because the substance circulates mainly through informal markets, verification is a recurring theme in technical discussion. Independent analyses have found that labeled content and actual content can diverge, and that purity varies between samples. Analytical laboratories use reversed-phase chromatography to separate components and mass spectrometry to confirm identity. Isotope-labeled internal standards improve quantification in complex matrices. Such methods describe what a sample contains but say nothing about its sterility, lawful status, or suitability for any use. Open questions remain about how consistently testing is applied across the supply chain.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
After the talks, Xi met with US business executives who joined the trip, telling them China's door would only open wider to US businesses, and that US companies were deeply involved in the Chinese economy, benefiting both sides. Afterwards, Xi and Trump visited the Temple of Heaven, which Trump called a "Great place, incredible", adding "China's beautiful". This made Trump the second US president to visit the Temple while in office, after President Gerald Ford did so in 1975. Later, Xi hosted Trump for a dinner banquet at the Golden Room of the Great Hall of the People. Xi gave a speech, where he said the "great rejuvenation of the Chinese nation" and "make America great again" can go hand in hand. He called the China–US relationship the most important in the world, adding that it concerns the well-being of the two countries of 1.7 billion population, and the interests of over 8 billion people in the world. After concluding his speech, he raised a toast to the development and future of the two countries. Afterwards, Trump gave a speech, praising the "magnificent welcome like no other" and said, "It was a great honour to be with Xi". He talked about the history of the relationship between two nations, saying "Benjamin Franklin published the sayings of Confucius in his colonial newspaper" and said a sculpture of Confucius was "carved into the face of the United States Supreme Court". He added "At the request of China's ambassador, it was president Theodore Roosevelt who provided the funds to establish Xi Jinping's alma mater, Tsinghua University".
== C == C-terminus - C4 photosynthesis - cadherin - calbindin -calcitonin - calcitonin gene-related peptide - calcitonin gene-related peptide receptor - calcitonin receptor - calcitriol receptor - calcium channel - calcium signaling - calcium-binding protein - calmodulin - calmodulin-binding protein - Calvin cycle - CAM photosynthesis - CAM plants - cancer - capsid - carbohydrate - carbon - carbon fixation - carboxylic acid - carcinoembryonic antigen - carrier - carrier protein - CAS registry number - casein - catabolism - catalyst - catalytic domain - CCR5 receptor - CD4 antigen - CD45 antigen - CD95 antigen - CDC28 protein kinase - cell - cell adhesion molecule - cell biology - cell cycle protein - cell membrane - cell membrane transport - cell nucleus - cell surface receptor - cellular respiration - cellulose - centriole - centromere - centrosome - chaperone - chelation - chemical biology - chemical bond - chemical compound - conformation - chemical element - chemical equilibrium - chemical formula - chemical nomenclature - chemical property - chemical reaction - chemical series - chemical thermodynamics - cheminformatics - chemiosmosis - chemiosmotic hypothesis - chemiosmotic potential - chemist - chemistry - chemistry basic topics - chemotroph - chemokine receptor - chemoreceptor - chiasma - chimera (protein) - chimeric protein - chirality - chloride channel - chlorophyll - chloroplast - chloroplast membrane - cholecystokinin receptor - cholesterine - cholinergic receptor - chorionic gonadotropin - chromatid - chromatin - ciclosporin - chromatography - chromosomal crossover - chromosome - chromosome walking - cilium - circular dichroism - cis face - citric acid - citric acid cycle - cladistics - cloning - coenzyme - cofactor (biochemistry) - colchicine - collagen - colloid - colony-stimulating factor - colony stimulating factor 1 receptor - colorimeter - comparative biochemistry - competitive inhibition - complement 3A - complement 5A - complement factor B - complement membrane attack complex - complement receptor - complex - computational biology - computational chemistry - computational genomics - concanavalin A - concentration - concentration gradient - consensus sequence - conserved sequence - cooperative - cooperative binding - cooperativity - cooperativity cellular respiration - corticotropin - corticotropin receptor - corticotropin-releasing hormone - corticotropin-releasing hormone receptor - cotransport metabolism - covalent bond - covalent radius - CpG island - cristae - cryptobiology - crystal structure - crystallography - cuticula - CXCR4 receptor - cyclic AMP receptor - cyclic AMP receptor protein - cyclic AMP-responsive DNA-binding protein - cyclic electron flow - cyclic nucleotide - cyclic peptide - cyclin - cyclin A - cyclin B - cyclin E - cyclin-dependent kinase - cycloleucine - cyclosporin - cyclosporine - cystatin - cysteine - cystic fibrosis transmembrane conductance regulator - cytochrome B - cytochrome C - cytochrome P-450 - cytochrome P-450 CYP1A1 - cytochrome C oxidase - cytokine receptor - cytoplasm - cytoplasmic and nuclear receptor - cytosine - cytoskeletal protein - cytoskeleton - cytosol - cytotoxic T cell
=== Phase 1 === Dexmedetomidine (BXCL-501; Igalmi; KalmPen) – α2-adrenergic receptor agonist [21] ENX-205 – dopamine D2 and D3 receptor antagonist and serotonin 5-HT1A and 5-HT2A receptor agonist [22] (R)-Midomafetamine ((R)-MDMA; EMP-01) – serotonin–norepinephrine releasing agent, weak serotonin 5-HT2 receptor agonist, and entactogen [23] Mirodenafil (AR-1001) – phosphodiesterase PDE5 inhibitor [24]
Sources: en.wikipedia.org
=== UK === In the UK, clinical psychologists undertake a Doctor of Clinical Psychology (DClinPsych), which is a practitioner doctorate with both clinical and research components. This is a three-year full-time salaried program sponsored by the National Health Service (NHS) and based in universities and the NHS. Entry into these programs is highly competitive and requires at least a three-year undergraduate degree in psychology plus some form of experience, usually in either the NHS as an assistant psychologist or in academia as a research assistant. It is not unusual for applicants to apply several times before being accepted onto a training course as only about one-fifth of applicants are accepted each year. These clinical psychology doctoral degrees are accredited by the British Psychological Society and the Health and Care Professions Council (HCPC). The HCPC is the statutory regulator for practitioner psychologists in the UK. Those who successfully complete clinical psychology doctoral degrees are eligible to apply for registration with the HPC as a clinical psychologist. In the UK, registration as a clinical psychologist with the Health and Care Professions Council (HCPC) is necessary. The HCPC is the statutory regulator for practitioner psychologists in the UK. In the UK the following titles are restricted by law "registered psychologist" and "practitioner psychologist"; in addition, the specialist title "clinical psychologist" is also restricted by law.
PF-04455242 is an experimental κ-opioid receptor (KOR) antagonist which was under development by Pfizer for the treatment of bipolar depression but was never marketed. Its development was discontinued in early clinical trials. It is taken by mouth.
==== Isomers ==== Alternative skeletal isomers of DOBU can also be produced, where the 4-(n-butyl) group of DOBU is replaced with any of the three other butyl isomers, the iso-butyl, sec-butyl and tert-butyl compounds being called DOIB, DOSB, and DOTB, respectively. All are significantly less potent than DOBU, with DOIB being active at around 10–15 mg, and DOSB at 25–30 mg. The most highly branched isomer DOTB was completely inactive in both animal and human trials. However, it was also reported that DOTB and DOAM partially generalized to DOM in animal drug discrimination tests.
=== Censorship === Twitter Blue Checkmarks have been removed or suspended from verified accounts as a form of censorship. Laura Loomer, a political activist, conspiracy theorist and Internet personality, was opposed to H-1B visas and then lost her blue checkmark on 27 December 2024. Gavin Mario Wax, ConservativePAC, and Owen Shroyer also affected.
Sources: en.wikipedia.org
Dry powder is usually held frozen, shielded from light, and kept away from moisture. Desiccant packaging limits hydrolysis during storage. Solutions are typically aliquoted and frozen once, because repeated thawing shortens useful life.
Mass spectrometry establishes molecular mass, and reversed-phase chromatography reports purity. Peptide mapping or amino acid analysis supports sequence-level confirmation. No single technique covers all failure modes, so laboratories combine results.
Common entries include appearance, purity by chromatographic area, measured mass, and sometimes residual solvents or counter-ion content. Methods and instrument conditions are not always described. The document reflects the supplier's own testing unless an independent laboratory is named.
No regulator in a major market has approved it for human use. It appears in research settings and in products marketed outside pharmacy channels. Legal status for personal possession varies by country.